Analysis
Pulse, per its own funding tracker, covered five separate moves in the IPO pipeline as they happened this week: nine new S-1 filings hitting the SEC in 48 hours, FireFly Robotics' direct listing, Centinel Spine's S-1, Retension Pharmaceuticals' second amendment, and Pine Tree Acquisition Corp.'s SPAC pricing. Read individually, each is a routine filing update. Read together, they show the same gap: filings are outrunning pricings.
Of those five stories, only one -- Pine Tree's SPAC -- actually priced and started trading this week, at $100 million under ticker PAXGU. FireFly's filing returns zero new capital to the company; it's existing shareholders registering 27.1 million shares for resale, not a capital raise. Centinel Spine's S-1 still carries blank placeholders for share count and price, meaning the company hasn't decided what it's actually selling yet. Retension's second S-1/A amendment in two days is still SEC back-and-forth, not a path to a pricing date.
“Of those five stories, only one -- Pine Tree's SPAC -- actually priced and started trading this week, at $100 million under ticker PAXGU.”
That one-in-five ratio -- filings and amendments vastly outnumbering actual completed pricings -- is the real state of the 2026 IPO window this week. Companies are willing to start the paperwork, but very few are willing to test where public investors will actually price them. A pipeline full of S-1s says more about issuers hedging their options than about investor demand, which is the gap a pure filing-count headline tends to miss.
